SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of ...
Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of ...
JOHOR BAHRU-A RM2.6 billion (S$788 million) development including a mall topped by four towers is being planned at the Johor Bahru terminus of the upcoming Johor Bahru-Singapore Rapid Transit ...
The RM2.6 billion (S$786 million) development is a strategic partnership between Malaysia's Mass Rapid Transit Corporation (MRT Corp) and Malaysian conglomerate Sunway Group. Both parties signed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results